Menu
R&D programs sponsored by national and international programs:
Generation of new multiplex assays with prognostic, diagnostic & predictive value on biological fluids other than blood, in patients with solid tumours.
Development of a platform for both better patient stratification & clinical validation efficiency of immuno oncology drugs.
Generation of new multiplex assays with prognostic, diagnostic & predictive value on biological fluids other than blood, in patients with solid tumours.
To develop an algorithm based on artificial intelligence methods to guide physicians on the decision-making process in the clinical setting.
R&D programs sponsored by:
Development of a liquid biopsy assay for the early detection of lung cancer.
Molecular classification neuroendocrine tumors of the lung.
Development of a liquid biopsy assay for the early detection of lung cancer.
Testing new therapeutic strategies for P53-mutated NSCLC patients.
Molecular classification neuroendocrine tumors of the lung.
To move the promising technology of liquid biopsies out of its infancy and bring it to the clinic with a further focus on Non-Small Cell Lung Cancer (NSCLC) early diagnosis. Liquid biopsies offer a minimally invasive, safe, and sensitive alternative or complementary approach for tissue biopsies.
Development of multiplexed panes for diagnostics in liquid biopsy and expansion of the single mutation test for the monitorization of not microcytic lung cancer.
Development of a platform for both better patient stratification & clinical validation efficiency of immuno oncology drugs.
Design and validation of a new diagnostics assay for the stratification of lung cancer patients presenting resistance to EGFR therapy.
Artificial intelligence (AI)-based digital tools for workflow improvement in pathological image.
PANGAEA ONCOLOGY. ALL RIGHTS RESERVED, 2024.
DESIGNED & PRODUCED BY SOTO BUSINESS PARTNERS